Yarrow Bioscience (YARW) Net Income (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Net Income came in at -$8000.0 in Q2 2025, up 27.27% YoY from -$6285.7 in Q2 2024, and little changed on a QoQ basis from -$8000.0 in Q1 2025.
Yarrow Bioscience (YARW) Net Income (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 9 years of Net Income data on file, last reported at -$8000.0 in Q2 2025.
- Quarterly Net Income rose 27.27% year-over-year to -$8000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$16000.0 (up 40.74% YoY) and the FY2025 annual result came in at $253000.0, up 1037.04% from the prior year.
- Net Income held at -$8000.0 in Q2 2025, from -$8000.0 in the prior quarter.
- In the past five years, Net Income ranged from a high of $13.4 million in Q1 2022 to a low of -$9.7 million in Q1 2021.
- A 5-year average of -$1.1 million and a median of -$36000.0 in 2023 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income surged 238.14% — and 2023, when it sank 151.47%.
- Tracing YARW's Net Income over 5 years: stood at -$3.2 million in 2021, then soared by 31.71% to -$2.2 million in 2022, then soared by 98.35% to -$36000.0 in 2023, then jumped by 77.78% to -$8000.0 in 2024, then changed by 0.0% to -$8000.0 in 2025.
- The last three Net Income figures came in at -$8000.0 (Q2 2025), -$8000.0 (Q1 2025), and -$8000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | -3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -108,000.00 |
| Jun 30, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -8,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | -36,000.00 |
| Sep 30, 2023 | -513,000.00 |
| Jun 30, 2023 | -20,000.00 |
| Mar 31, 2023 | -10,000.00 |
| Dec 31, 2022 | -2.18 Mn |
| Sep 30, 2022 | -204,000.00 |
| Jun 30, 2022 | -241,000.00 |
| Mar 31, 2022 | 13.36 Mn |
| Dec 31, 2021 | -3.20 Mn |
| Sep 30, 2021 | -7.01 Mn |
| Jun 30, 2021 | -9.24 Mn |
| Mar 31, 2021 | -9.67 Mn |
| Dec 31, 2020 | -23.18 Mn |
| Sep 30, 2020 | -24.71 Mn |